Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Identifieur interne : 001457 ( PubMed/Corpus ); précédent : 001456; suivant : 001458Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Auteurs : Jason Grebely ; Stefan Mauss ; Ashley Brown ; Jean-Pierre Bronowicki ; Massimo Puoti ; David Wyles ; Macky Natha ; Yanni Zhu ; Junming Yang ; Bruce Kreter ; Diana M. Brainard ; Chohee Yun ; Val Carr ; Gregory J. DoreSource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Antiviral Agents (therapeutic use), Benzimidazoles (administration & dosage), Benzimidazoles (adverse effects), Benzimidazoles (therapeutic use), Data Interpretation, Statistical, Drug Therapy, Combination (adverse effects), Drug Users, Enzyme-Linked Immunosorbent Assay, Female, Fluorenes (administration & dosage), Fluorenes (adverse effects), Fluorenes (therapeutic use), Genotype, Hepacivirus (drug effects), Hepacivirus (genetics), Hepatitis C, Chronic (blood), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (genetics), Humans, Male, Middle Aged, Opiate Substitution Treatment, Retrospective Studies, Ribavirin (administration & dosage), Ribavirin (adverse effects), Ribavirin (therapeutic use), Sofosbuvir (administration & dosage), Sofosbuvir (adverse effects), Sofosbuvir (therapeutic use), Sustained Virologic Response, Viral Load (drug effects).
- MESH :
- chemical , administration & dosage : Benzimidazoles, Fluorenes, Ribavirin, Sofosbuvir.
- chemical , adverse effects : Benzimidazoles, Fluorenes, Ribavirin, Sofosbuvir.
- chemical , therapeutic use : Antiviral Agents, Benzimidazoles, Fluorenes, Ribavirin, Sofosbuvir.
- adverse effects : Drug Therapy, Combination.
- blood : Hepatitis C, Chronic.
- drug effects : Hepacivirus, Viral Load.
- drug therapy : Hepatitis C, Chronic.
- genetics : Hepacivirus, Hepatitis C, Chronic.
- Adult, Data Interpretation, Statistical, Drug Users, Enzyme-Linked Immunosorbent Assay, Female, Genotype, Humans, Male, Middle Aged, Opiate Substitution Treatment, Retrospective Studies, Sustained Virologic Response.
Abstract
Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low. Our aim was to evaluate the impact of OST and drug use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sofosbuvir ± ribavirin.
DOI: 10.1093/cid/ciw580
PubMed: 27553375
Links to Exploration step
pubmed:27553375Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.</title><author><name sortKey="Grebely, Jason" sort="Grebely, Jason" uniqKey="Grebely J" first="Jason" last="Grebely">Jason Grebely</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation></affiliation></author><author><name sortKey="Mauss, Stefan" sort="Mauss, Stefan" uniqKey="Mauss S" first="Stefan" last="Mauss">Stefan Mauss</name><affiliation><nlm:affiliation>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, Ashley" sort="Brown, Ashley" uniqKey="Brown A" first="Ashley" last="Brown">Ashley Brown</name><affiliation><nlm:affiliation>Liver Unit, Department of Medicine, St Mary's Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name><affiliation><nlm:affiliation>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><affiliation><nlm:affiliation>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Wyles, David" sort="Wyles, David" uniqKey="Wyles D" first="David" last="Wyles">David Wyles</name><affiliation><nlm:affiliation>Division of Infectious Diseases, University of California, San Diego.</nlm:affiliation></affiliation></author><author><name sortKey="Natha, Macky" sort="Natha, Macky" uniqKey="Natha M" first="Macky" last="Natha">Macky Natha</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Junming" sort="Yang, Junming" uniqKey="Yang J" first="Junming" last="Yang">Junming Yang</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Kreter, Bruce" sort="Kreter, Bruce" uniqKey="Kreter B" first="Bruce" last="Kreter">Bruce Kreter</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Yun, Chohee" sort="Yun, Chohee" uniqKey="Yun C" first="Chohee" last="Yun">Chohee Yun</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Carr, Val" sort="Carr, Val" uniqKey="Carr V" first="Val" last="Carr">Val Carr</name><affiliation><nlm:affiliation>Gilead Sciences, Stockley Park, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27553375</idno><idno type="pmid">27553375</idno><idno type="doi">10.1093/cid/ciw580</idno><idno type="wicri:Area/PubMed/Corpus">001457</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001457</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.</title><author><name sortKey="Grebely, Jason" sort="Grebely, Jason" uniqKey="Grebely J" first="Jason" last="Grebely">Jason Grebely</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation></affiliation></author><author><name sortKey="Mauss, Stefan" sort="Mauss, Stefan" uniqKey="Mauss S" first="Stefan" last="Mauss">Stefan Mauss</name><affiliation><nlm:affiliation>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Brown, Ashley" sort="Brown, Ashley" uniqKey="Brown A" first="Ashley" last="Brown">Ashley Brown</name><affiliation><nlm:affiliation>Liver Unit, Department of Medicine, St Mary's Hospital, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Bronowicki, Jean Pierre" sort="Bronowicki, Jean Pierre" uniqKey="Bronowicki J" first="Jean-Pierre" last="Bronowicki">Jean-Pierre Bronowicki</name><affiliation><nlm:affiliation>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France.</nlm:affiliation></affiliation></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><affiliation><nlm:affiliation>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Wyles, David" sort="Wyles, David" uniqKey="Wyles D" first="David" last="Wyles">David Wyles</name><affiliation><nlm:affiliation>Division of Infectious Diseases, University of California, San Diego.</nlm:affiliation></affiliation></author><author><name sortKey="Natha, Macky" sort="Natha, Macky" uniqKey="Natha M" first="Macky" last="Natha">Macky Natha</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Zhu, Yanni" sort="Zhu, Yanni" uniqKey="Zhu Y" first="Yanni" last="Zhu">Yanni Zhu</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Yang, Junming" sort="Yang, Junming" uniqKey="Yang J" first="Junming" last="Yang">Junming Yang</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Kreter, Bruce" sort="Kreter, Bruce" uniqKey="Kreter B" first="Bruce" last="Kreter">Bruce Kreter</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Brainard, Diana M" sort="Brainard, Diana M" uniqKey="Brainard D" first="Diana M" last="Brainard">Diana M. Brainard</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Yun, Chohee" sort="Yun, Chohee" uniqKey="Yun C" first="Chohee" last="Yun">Chohee Yun</name><affiliation><nlm:affiliation>Gilead Sciences, Foster City, California.</nlm:affiliation></affiliation></author><author><name sortKey="Carr, Val" sort="Carr, Val" uniqKey="Carr V" first="Val" last="Carr">Val Carr</name><affiliation><nlm:affiliation>Gilead Sciences, Stockley Park, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Dore, Gregory J" sort="Dore, Gregory J" uniqKey="Dore G" first="Gregory J" last="Dore">Gregory J. Dore</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiviral Agents (therapeutic use)</term><term>Benzimidazoles (administration & dosage)</term><term>Benzimidazoles (adverse effects)</term><term>Benzimidazoles (therapeutic use)</term><term>Data Interpretation, Statistical</term><term>Drug Therapy, Combination (adverse effects)</term><term>Drug Users</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Fluorenes (administration & dosage)</term><term>Fluorenes (adverse effects)</term><term>Fluorenes (therapeutic use)</term><term>Genotype</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (genetics)</term><term>Hepatitis C, Chronic (blood)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Hepatitis C, Chronic (genetics)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Opiate Substitution Treatment</term><term>Retrospective Studies</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (adverse effects)</term><term>Ribavirin (therapeutic use)</term><term>Sofosbuvir (administration & dosage)</term><term>Sofosbuvir (adverse effects)</term><term>Sofosbuvir (therapeutic use)</term><term>Sustained Virologic Response</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Benzimidazoles</term><term>Fluorenes</term><term>Ribavirin</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzimidazoles</term><term>Fluorenes</term><term>Ribavirin</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Benzimidazoles</term><term>Fluorenes</term><term>Ribavirin</term><term>Sofosbuvir</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepacivirus</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepacivirus</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Data Interpretation, Statistical</term><term>Drug Users</term><term>Enzyme-Linked Immunosorbent Assay</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Opiate Substitution Treatment</term><term>Retrospective Studies</term><term>Sustained Virologic Response</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"> Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low. Our aim was to evaluate the impact of OST and drug use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sofosbuvir ± ribavirin.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27553375</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>24</Day></DateCreated><DateCompleted><Year>2017</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.</ArticleTitle><Pagination><MedlinePgn>1405-1411</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND"> Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low. Our aim was to evaluate the impact of OST and drug use during therapy on completion, adherence, sustained virologic response (SVR12), and safety of ledipasvir/sofosbuvir ± ribavirin.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS"> The phase 3 ION studies evaluated a fixed-dose combination of ledipasvir/sofosbuvir ± ribavirin administered for 8, 12, or 24 weeks in patients with chronic HCV genotype 1. People with clinically significant drug use (prior 12 months) or noncannabinoids detected at screening by urine drug tests (not explained by prescriptions) were ineligible. Stored samples were available from ION-1 for retrospective testing for illicit drugs by enzyme-linked immunosorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS"> Among 1952 patients enrolled in the ION studies, 4% (n = 70) were receiving OST. Among those receiving (n = 70) and not receiving OST (n = 1882), there was no difference in treatment completion (97% vs 98%; P = .40), ≥80% adherence (93% vs 92%; P = 1.00), SVR12 (94% vs 97%; P = .28), and serious adverse events (4% vs 3%; P = .43), respectively. Among participants in the ION-1 trial, 23% (n = 196) used illicit drugs during therapy (15% cannabinoids alone; 8% other illicit drugs ± cannabinoids). There was no difference in treatment completion, ≥80% adherence, SVR12, or serious AEs in those with no drug use during treatment compared with those who used cannabinoids and/or other illicit drugs. No cases of HCV reinfection were observed in the 24 weeks following treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS"> OST and drug use during HCV therapy did not impact treatment completion, adherence, SVR12, or safety.</AbstractText><AbstractText Label="CLINICAL TRIALS REGISTRATION" NlmCategory="BACKGROUND"> ION-1 (NCT01701401); ION-2 (NCT01768286); and ION-3 (NCT01851330).</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grebely</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mauss</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Liver Unit, Department of Medicine, St Mary's Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bronowicki</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>INSERM U954, Universitary Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puoti</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyles</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, University of California, San Diego.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natha</LastName><ForeName>Macky</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yanni</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Junming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreter</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brainard</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Chohee</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carr</LastName><ForeName>Val</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Stockley Park, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dore</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01701401</AccessionNumber><AccessionNumber>NCT01768286</AccessionNumber><AccessionNumber>NCT01851330</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>013TE6E4WV</RegistryNumber><NameOfSubstance UI="C586541">ledipasvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WJ6CA3ZU8B</RegistryNumber><NameOfSubstance UI="D000069474">Sofosbuvir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055030" MajorTopicYN="Y">Drug Users</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019698" MajorTopicYN="N">Hepatitis C, Chronic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058850" MajorTopicYN="Y">Opiate Substitution Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069474" MajorTopicYN="N">Sofosbuvir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072230" MajorTopicYN="N">Sustained Virologic Response</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DAA</Keyword><Keyword MajorTopicYN="N">PWID</Keyword><Keyword MajorTopicYN="N">drug use</Keyword><Keyword MajorTopicYN="N">hepatitis C virus</Keyword><Keyword MajorTopicYN="N">opioid substitution therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27553375</ArticleId><ArticleId IdType="pii">ciw580</ArticleId><ArticleId IdType="doi">10.1093/cid/ciw580</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001457 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001457 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27553375
|texte= Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27553375" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |